Experimental cell therapy targets rare Muscle-Weakening disease

NCT ID NCT05451212

Completed Disease control Sponsor: Cabaletta Bio Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated Jun 12, 2026 · Updated 33 times

Summary

This early-stage study tested a new cell therapy called MuSK-CAART in 7 people with a rare, severe form of myasthenia gravis (MuSK MG). The treatment uses a patient's own immune cells, modified to attack the harmful antibodies causing the disease. The main goal was to check safety and find the right dose, with the hope of achieving long-term remission.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MUSK MYASTHENIA GRAVIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Houston Methodist Hospital

Houston, Texas, 77030, United States
Oregon Health & Science University (OHSU)

Portland, Oregon, 97239, United States
UC Davis, Department of Neurology

Sacramento, California, 95817, United States
UC Irvine, Department of Neurology

Orange, California, 92868, United States
University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

Conditions

The condition(s) this trial relates to.

autoimmune disease immune system disorder Muscle Weakness musculoskeletal system disorder myasthenia gravis neuromuscular disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MUSK MYASTHENIA GRAVIS